Gossamer Bio (NASDAQ:GOSS – Get Free Report) and IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.
Profitability
This table compares Gossamer Bio and IDEAYA Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Gossamer Bio | -235.00% | N/A | -112.04% |
| IDEAYA Biosciences | -75.93% | -16.73% | -15.34% |
Analyst Recommendations
This is a breakdown of current ratings for Gossamer Bio and IDEAYA Biosciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Gossamer Bio | 2 | 3 | 5 | 0 | 2.30 |
| IDEAYA Biosciences | 1 | 1 | 14 | 0 | 2.81 |
Gossamer Bio presently has a consensus target price of $256.00, indicating a potential upside of 2,430.64%. IDEAYA Biosciences has a consensus target price of $53.42, indicating a potential upside of 50.35%. Given Gossamer Bio’s higher probable upside, equities analysts plainly believe Gossamer Bio is more favorable than IDEAYA Biosciences.
Institutional & Insider Ownership
81.2% of Gossamer Bio shares are held by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are held by institutional investors. 4.2% of Gossamer Bio shares are held by company insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Volatility & Risk
Gossamer Bio has a beta of 2.21, indicating that its share price is 121% more volatile than the S&P 500. Comparatively, IDEAYA Biosciences has a beta of -0.04, indicating that its share price is 104% less volatile than the S&P 500.
Valuation & Earnings
This table compares Gossamer Bio and IDEAYA Biosciences”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Gossamer Bio | $48.47 million | 1.28 | -$170.37 million | ($56.00) | -0.18 |
| IDEAYA Biosciences | $234.13 million | 13.33 | -$113.70 million | ($1.94) | -18.31 |
IDEAYA Biosciences has higher revenue and earnings than Gossamer Bio. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
Summary
IDEAYA Biosciences beats Gossamer Bio on 10 of the 14 factors compared between the two stocks.
About Gossamer Bio
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
About IDEAYA Biosciences
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.
